These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 22787013)

  • 1. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.
    van der Werf C; Nederend I; Hofman N; van Geloven N; Ebink C; Frohn-Mulder IM; Alings AM; Bosker HA; Bracke FA; van den Heuvel F; Waalewijn RA; Bikker H; van Tintelen JP; Bhuiyan ZA; van den Berg MP; Wilde AA
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):748-56. PubMed ID: 22787013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients.
    Postma AV; Denjoy I; Kamblock J; Alders M; Lupoglazoff JM; Vaksmann G; Dubosq-Bidot L; Sebillon P; Mannens MM; Guicheney P; Wilde AA
    J Med Genet; 2005 Nov; 42(11):863-70. PubMed ID: 16272262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and mutational analysis of the RyR2 gene in seven Czech families with catecholaminergic polymorphic ventricular tachycardia.
    Andrsova I; Valaskova I; Kubus P; Vit P; Gaillyova R; Kadlecova J; Manouskova L; Novotny T
    Pacing Clin Electrophysiol; 2012 Jul; 35(7):798-803. PubMed ID: 22519458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exon 3 deletion of RYR2 encoding cardiac ryanodine receptor is associated with left ventricular non-compaction.
    Ohno S; Omura M; Kawamura M; Kimura H; Itoh H; Makiyama T; Ushinohama H; Makita N; Horie M
    Europace; 2014 Nov; 16(11):1646-54. PubMed ID: 24394973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic characterization of familial CPVT after 30 years.
    Beery TA; Shah MJ; Benson DW
    Biol Res Nurs; 2009 Jul; 11(1):66-72. PubMed ID: 19398417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide experience of catecholaminergic polymorphic ventricular tachycardia caused by RyR2 mutations.
    Broendberg AK; Nielsen JC; Bjerre J; Pedersen LN; Kristensen J; Henriksen FL; Bundgaard H; Jensen HK
    Heart; 2017 Jun; 103(12):901-909. PubMed ID: 28237968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations.
    Miyata K; Ohno S; Itoh H; Horie M
    Intern Med; 2018 Jul; 57(13):1813-1817. PubMed ID: 29434162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
    Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
    Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
    Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
    Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
    Haugaa KH; Leren IS; Berge KE; Bathen J; Loennechen JP; Anfinsen OG; Früh A; Edvardsen T; Kongsgård E; Leren TP; Amlie JP
    Europace; 2010 Mar; 12(3):417-23. PubMed ID: 20106799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
    Wangüemert F; Bosch Calero C; Pérez C; Campuzano O; Beltran-Alvarez P; Scornik FS; Iglesias A; Berne P; Allegue C; Ruiz Hernandez PM; Brugada J; Pérez GJ; Brugada R
    Heart Rhythm; 2015 Jul; 12(7):1636-43. PubMed ID: 25814417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetics of exercise-induced polymorphic ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms.
    Laitinen PJ; Swan H; Kontula K
    Eur J Hum Genet; 2003 Nov; 11(11):888-91. PubMed ID: 14571276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves.
    Paavola J; Viitasalo M; Laitinen-Forsblom PJ; Pasternack M; Swan H; Tikkanen I; Toivonen L; Kontula K; Laine M
    Eur Heart J; 2007 May; 28(9):1135-42. PubMed ID: 17347175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry.
    Roston TM; Yuchi Z; Kannankeril PJ; Hathaway J; Vinocur JM; Etheridge SP; Potts JE; Maginot KR; Salerno JC; Cohen MI; Hamilton RM; Pflaumer A; Mohammed S; Kimlicka L; Kanter RJ; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Choi SHJ; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Van Petegem F; Sanatani S
    Europace; 2018 Mar; 20(3):541-547. PubMed ID: 28158428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
    Hayashi M; Denjoy I; Extramiana F; Maltret A; Buisson NR; Lupoglazoff JM; Klug D; Hayashi M; Takatsuki S; Villain E; Kamblock J; Messali A; Guicheney P; Lunardi J; Leenhardt A
    Circulation; 2009 May; 119(18):2426-34. PubMed ID: 19398665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac arrest in a mother and daughter and the identification of a novel RYR2 variant, predisposing to low penetrant catecholaminergic polymorphic ventricular tachycardia in a four-generation Canadian family.
    Tung M; Van Petegem F; Lauson S; Collier A; Hodgkinson K; Fernandez B; Connors S; Leather R; Sanatani S; Arbour L
    Mol Genet Genomic Med; 2020 Apr; 8(4):e1151. PubMed ID: 31994352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment?
    Hofman N; Tan HL; Alders M; van Langen IM; Wilde AA
    J Am Coll Cardiol; 2010 Jun; 55(23):2570-6. PubMed ID: 20513597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.
    Hayashi M; Denjoy I; Hayashi M; Extramiana F; Maltret A; Roux-Buisson N; Lupoglazoff JM; Klug D; Maury P; Messali A; Guicheney P; Leenhardt A
    Europace; 2012 Sep; 14(9):1344-51. PubMed ID: 22383456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
    Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
    Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Pflaumer A; Davis AM
    Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.